Submissions for variant NM_019109.5(ALG1):c.773C>T (p.Ser258Leu)

gnomAD frequency: 0.00036  dbSNP: rs28939378

Total submissions: 21

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Eurofins Ntd Llc (ga)	RCV000081987	SCV000232284	pathogenic	not provided	2014-10-28	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000210565	SCV000262918	pathogenic	Inborn genetic diseases	2014-02-06	criteria provided, single submitter	clinical testing
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology	RCV000004989	SCV000265559	likely pathogenic	ALG1-congenital disorder of glycosylation	2017-02-09	criteria provided, single submitter	research
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics	RCV000081987	SCV000511284	pathogenic	not provided	2016-11-07	criteria provided, single submitter	clinical testing
GeneDx	RCV000081987	SCV000617787	pathogenic	not provided	2021-10-28	criteria provided, single submitter	clinical testing	Published functional studies demonstrate a damaging effect (Grubenmann et al., 2004); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21228398, 14709599, 26931382, 14973782, 27325525, 28554332, 30609409, 31618474, 31994750, 32573669)
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000606536	SCV000731828	pathogenic	Congenital disorder of glycosylation	2017-09-26	criteria provided, single submitter	clinical testing	The p.Ser258Leu variant in ALG1 has been reported in at least 10 homozygous and 14 compound heterozygous individuals with a congenital disorder of glycosylation (Grubenmann 2004, Schwarz 2004, Kranz 2004, Harshman 2016, Ng 2016, Park 2016, Barba 2016, and Bowling 2017), and has also been reported in ClinVar (Variation ID#4724). In vitro functional studies provide evidence that the p.Ser258ZLeu var iant impacts the protein (Grubenmann 2004, Schwarz 2004, Kranz 2004, and Ng 2016 ). This variant has been identified in 0.05% (67/126078) of European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; d bSNP rs28939378). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency . In summary, although additional studies are required to fully establish its c linical significance, the p.Ser258Leu variant is pathogenic for congenital disor ders of glycosylation in an autosomal recessive manner based on functional studi es and its occurrence in individuals with this disease.
Genome Diagnostics Laboratory, University Medical Center Utrecht	RCV000004989	SCV000743746	likely pathogenic	ALG1-congenital disorder of glycosylation	2017-07-28	criteria provided, single submitter	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000004989	SCV000745150	pathogenic	ALG1-congenital disorder of glycosylation	2017-05-31	criteria provided, single submitter	clinical testing
Fulgent Genetics, Fulgent Genetics	RCV000004989	SCV000893399	pathogenic	ALG1-congenital disorder of glycosylation	2018-10-31	criteria provided, single submitter	clinical testing
Invitae	RCV000004989	SCV000932120	pathogenic	ALG1-congenital disorder of glycosylation	2024-01-22	criteria provided, single submitter	clinical testing	This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 258 of the ALG1 protein (p.Ser258Leu). This variant is present in population databases (rs28939378, gnomAD 0.05%). This missense change has been observed in individuals with congenital disorder of glycosylation (PMID: 14709599, 14973778, 14973782, 20679665, 22966035, 26931382, 27172925, 27325525, 28554332). ClinVar contains an entry for this variant (Variation ID: 4724). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ALG1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects ALG1 function (PMID: 14973778, 22966035, 26931382). For these reasons, this variant has been classified as Pathogenic.
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV000004989	SCV001245000	pathogenic	ALG1-congenital disorder of glycosylation	2022-04-01	criteria provided, single submitter	clinical testing	0102 - Loss of function is a known mechanism of disease in this gene and is associated with congenital disorder of glycosylation, type Ik (MIM#608540). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from serine to leucine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (87 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (1 heterozygote, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported as homozygous or compound heterozygous in many individuals with type I congenital disorder of glycosylation (PMID: 26931382). It has also been reported as likely pathogenic/pathogenic many times in ClinVar. (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne	RCV001526585	SCV001737012	pathogenic	Encephalopathy		criteria provided, single submitter	research
Revvity Omics, Revvity	RCV000004989	SCV002024960	pathogenic	ALG1-congenital disorder of glycosylation	2019-05-23	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000004989	SCV002547522	pathogenic	ALG1-congenital disorder of glycosylation	2022-05-03	criteria provided, single submitter	clinical testing	Variant summary: ALG1 c.773C>T (p.Ser258Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0003 in 250018 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ALG1 causing Congenital Disorder Of Glycosylation Type 1K (0.0003 vs 0.0011), allowing no conclusion about variant significance. c.773C>T has been reported in the literature in multiple individuals affected with Congenital Disorder Of Glycosylation Type 1K both in the homozygous and compound heterozygous state (Han_2020, Kranz_2004, Ng_2016). Functional studies have shown the variant to disrupt normal ALG1 enzymatic function (eg. Kranz_2004). 12 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
3billion	RCV000004989	SCV002572775	likely pathogenic	ALG1-congenital disorder of glycosylation	2022-09-01	criteria provided, single submitter	clinical testing	The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.031%). The variant is in trans with NM_019109.5:c.826C>T. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.61; 3Cnet: 0.25). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000004724). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline.
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego	RCV000004989	SCV004046113	pathogenic	ALG1-congenital disorder of glycosylation		criteria provided, single submitter	clinical testing	This variant has been previously reported as a compound heterozygous and homozygous change in patients with Congenital disorder of glycosylation, type Ik (PMID: 14709599, 27325525, 26931382), and as a compound heterozygous change in patients with seizure disorders (PMID: 28554332, 31618474). This variant could not rescue growth in an alg-1 deficient yeast strain, suggesting that the variant affects protein function (PMID: 14709599, 26931382). It is present in the heterozygous state in the gnomAD population database at a frequency of .03% (87/281390) and thus is presumed to be rare. The c.773C>T (p.Ser258Leu) variant is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.773C>T (p.Ser258Leu) variant is classified as Pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV000004989	SCV004563244	pathogenic	ALG1-congenital disorder of glycosylation	2023-10-17	criteria provided, single submitter	clinical testing	The ALG1 c.773C>T; p.Ser258Leu variant (rs28939378) is reported in the literature in the compound heterozygous or homozygous state in individuals affected with congenital disorders of glycosylation (Barba 2016, Bell 2011, Bowling 2017, Grubenmann 2004, Han 2020, Harshman 2016, Kranz 2004, Lipinski 2021, Ng 2016, Schwarz 2004). Functional analyses demonstrate reduced enzyme function (Grubenmann 2004, Kranz 2004, Ng 2016, Schwarz 2004). This variant is also reported in ClinVar (Variation ID: 4724), and is found in the general population with an overall allele frequency of 0.031% (87/281390 alleles) in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.615). Based on available information, this variant is considered to be pathogenic. References: Barba C et al. Congenital disorders of glycosylation presenting as epileptic encephalopathy with migrating partial seizures in infancy. Dev Med Child Neurol. 2016 Oct;58(10):1085-91. PMID: 27172925. Bell CJ et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011 Jan 12;3(65):65ra4. PMID: 21228398. Bowling KM et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med. 2017 May 30;9(1):43. PMID: 28554332. Grubenmann CE et al. Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik. Hum Mol Genet. 2004 Mar 1;13(5):535-42. PMID: 14709599. Han J et al. Rapid prenatal diagnosis of skeletal dysplasia using medical trio exome sequencing: Benefit for prenatal counseling and pregnancy management. Prenat Diagn. 2020 Apr;40(5):577-584. PMID: 31994750. Harshman LA et al. Congenital nephrotic syndrome in an infant with ALG1-congenital disorder of glycosylation. Pediatr Int. 2016 Aug;58(8):785-8. PMID: 27325525. Kranz C et al. Congenital disorder of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase I. Am J Hum Genet. 2004 Mar;74(3):545-51. PMID: 14973782. Lipinski P et al. Congenital disorders of glycosylation: Prevalence, incidence and mutational spectrum in the Polish population. Mol Genet Metab Rep. 2021 Feb 11;27:100726. PMID: 33643843. Ng BG et al. ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients. Hum Mutat. 2016 Jul;37(7):653-60. PMID: 26931382. Schwarz M et al. Deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase causes congenital disorder of glycosylation type Ik. Am J Hum Genet. 2004 Mar;74(3):472-81. PMID: 14973778.
OMIM	RCV000004989	SCV000025165	pathogenic	ALG1-congenital disorder of glycosylation	2004-03-01	no assertion criteria provided	literature only
University of Washington Center for Mendelian Genomics, University of Washington	RCV000655875	SCV000748668	likely pathogenic	Finnish congenital nephrotic syndrome	2016-06-21	no assertion criteria provided	research
University of Washington Center for Mendelian Genomics, University of Washington	RCV000606536	SCV000993477	likely pathogenic	Congenital disorder of glycosylation	2017-05-25	no assertion criteria provided	research
GenomeConnect - Invitae Patient Insights Network	RCV003483423	SCV004228847	not provided	ALG12-congenital disorder of glycosylation		no assertion provided	phenotyping only	Variant interpreted as Pathogenic and reported on 01-08-2021 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.